title: Preparation, characterization, and biological analysis of liposomal formulations of vincristine.
abstract: Vincristine is a dimeric Catharanthus alkaloid derived from the Madagascan periwinkle that acts by binding to tubulin and blocking metaphase in actively dividing cells. While vincristine is widely used in the treatment of a number of human carcinomas, its use is associated with dose-limiting neurotoxicity, manifested mainly as peripheral neuropathy. It is known that the therapeutic activity of vincristine can be significantly enhanced after its encapsulation in appropriately designed liposomal systems. Enhanced efficacy is also associated with a slight decrease in drug toxicity. Thus, the therapeutic index of vincristine can be enhanced significantly through the use of a liposomal delivery system. Vincristine may be encapsulated into liposomes of varying lipid composition by several techniques, including passive loading, pH gradient loading, and ionophore-assisted loading. However, most research has focused on the encapsulation of vincristine in response to a transbilayer pH gradient, which actively concentrates the drug within the aqueous interior of the liposome. This chapter details the preparation and evaluation of liposomal vincristine. Specifically, we elaborate on the components (choice of lipids, molar proportions, etc.), methods (preparation of liposomes, drug loading methods, etc.), critical design features (size, surface charge, etc.), and key biological endpoints (circulation lifetime, bioavailability, efficacy measurements) important to the development of a formulation of vincristine with enhanced therapeutic properties.
authors.affiliation: Department of Advanced Therapeutics, British Columbia Cancer Agency, British Columbia, Canada.
authors.forename: Dawn N
authors.initials: DN
authors.lastname: Waterhouse
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Madden
authors.forename: Pieter R
authors.initials: PR
authors.lastname: Cullis
authors.forename: Marcel B
authors.initials: MB
authors.lastname: Bally
authors.forename: Lawrence D
authors.initials: LD
authors.lastname: Mayer
authors.forename: Murray S
authors.initials: MS
authors.lastname: Webb
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D004337:Drug Carriers; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007476:Ionophores / Q000378:metabolism; D008055:Lipids / Q000737:chemistry; D008081:Liposomes / Q000138:chemical synthesis / Q000737:chemistry; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D014750:Vincristine / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D007476:Ionophores; D008055:Lipids; D008081:Liposomes; D014750:Vincristine